AVAI BIO, INC.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $276.3K | — | — | $1.4M | — |
| Cost of Revenue | — | — | — | $276.3K | $710.5K | $1.2M | $461.1K | $0 |
| Gross Profit | — | — | — | $-40.5K | $-210.8K | $-16.5K | $-256.3K | $0 |
| Gross Margin | — | — | — | -14.6% | — | — | -17.9% | — |
| Operating Expenses | ||||||||
| Research & Development | $15.0K | — | — | — | — | — | $27.0K | $0 |
| SG&A Expense | $792.3K | $762.5K | $1.4M | $234.9K | $449.4K | $205.3K | $229.4K | $39.0K |
| Operating Income | $-1.7M | $-1.1M | $-2.1M | $-348.9K | $126.5K | $302.3K | $69.6K | $-78.2K |
| Operating Margin | — | — | — | -126.3% | — | — | 4.9% | — |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | $-78.2K |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | $-1.7M | $-1.1M | $-2.1M | $-348.9K | $-126.5K | $-302.3K | $-69.6K | $-78.2K |
| Net Margin | — | — | — | -126.3% | — | — | -4.9% | — |
| EPS (Basic) | $-0.01 | $-0.01 | $-0.02 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| EPS (Diluted) | — | — | — | — | — | — | $0.00 | $0.00 |
| Shares Outstanding (Basic) | 138.0M | 128.1M | 86.5M | 77.0M | 52.6M | 52.6M | — | — |
| Shares Outstanding (Diluted) | 138.0M | 128.1M | 86.5M | 77.0M | 52.6M | 52.6M | 52.9M | 241.1M |
| Dividends Per Share | — | — | — | — | — | — | — | $0.00 |